Jiangsu Lianhuan Pharmaceutical Co Ltd (600513) — Net Asset Quality Index
Jiangsu Lianhuan Pharmaceutical Co Ltd (600513) has a Net Asset Quality Index of 40.6% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥4.16 Billion minus total liabilities of CN¥2.47 Billion yields net assets of CN¥1.69 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Read Jiangsu Lianhuan Pharmaceutical Co Ltd (600513) total liabilities for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Jiangsu Lianhuan Pharmaceutical Co Ltd Net Asset Quality Index Over Time (2000–2024)
This chart shows how Jiangsu Lianhuan Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 25 annual periods from 2000 to 2024. As of March 2026, the index stands at 40.6%, representing net assets of CN¥1.69 Billion against total assets of CN¥4.16 Billion CNY. For live market cap and overall valuation, see Jiangsu Lianhuan Pharmaceutical Co Ltd stock valuation.
Annual Net Asset Quality Index for Jiangsu Lianhuan Pharmaceutical Co Ltd (2000–2024)
The table below presents the year-by-year Net Asset Quality Index for Jiangsu Lianhuan Pharmaceutical Co Ltd from 2000 to 2024, covering 25 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check how strategically is Jiangsu Lianhuan Pharmaceutical Co Ltd's equity deployed to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 52.2% | CN¥1.58 Billion | CN¥3.02 Billion | CN¥1.44 Billion | ▼ -0.9 pp |
| 2023 | 53.1% | CN¥1.52 Billion | CN¥2.86 Billion | CN¥1.34 Billion | ▲ +1.1 pp |
| 2022 | 52.1% | CN¥1.41 Billion | CN¥2.71 Billion | CN¥1.30 Billion | ▼ -2.3 pp |
| 2021 | 54.4% | CN¥1.28 Billion | CN¥2.35 Billion | CN¥1.07 Billion | ▼ -3.3 pp |
| 2020 | 57.7% | CN¥1.18 Billion | CN¥2.05 Billion | CN¥867.05 Million | ▲ +0.3 pp |
| 2019 | 57.4% | CN¥1.08 Billion | CN¥1.89 Billion | CN¥805.57 Million | ▼ -9.3 pp |
| 2018 | 66.7% | CN¥946.61 Million | CN¥1.42 Billion | CN¥473.43 Million | ▼ -8.8 pp |
| 2017 | 75.4% | CN¥878.23 Million | CN¥1.16 Billion | CN¥286.25 Million | ▼ -2.2 pp |
| 2016 | 77.6% | CN¥827.25 Million | CN¥1.07 Billion | CN¥239.03 Million | ▲ +0.1 pp |
| 2015 | 77.4% | CN¥774.88 Million | CN¥1.00 Billion | CN¥225.66 Million | ▲ +11.5 pp |
| 2014 | 65.9% | CN¥434.25 Million | CN¥658.96 Million | CN¥224.71 Million | ▲ +4.0 pp |
| 2013 | 61.9% | CN¥402.11 Million | CN¥649.48 Million | CN¥247.36 Million | ▼ -17.2 pp |
| 2012 | 79.1% | CN¥350.42 Million | CN¥443.21 Million | CN¥92.79 Million | ▲ +0.8 pp |
| 2011 | 78.3% | CN¥327.61 Million | CN¥418.52 Million | CN¥90.91 Million | ▲ +1.2 pp |
| 2010 | 77.0% | CN¥308.95 Million | CN¥401.08 Million | CN¥92.13 Million | ▲ +0.4 pp |
| 2009 | 76.7% | CN¥293.89 Million | CN¥383.36 Million | CN¥89.47 Million | ▼ -1.7 pp |
| 2008 | 78.3% | CN¥281.68 Million | CN¥359.66 Million | CN¥77.98 Million | ▲ +2.8 pp |
| 2007 | 75.5% | CN¥269.97 Million | CN¥357.66 Million | CN¥87.69 Million | ▼ -1.7 pp |
| 2006 | 77.2% | CN¥259.20 Million | CN¥335.84 Million | CN¥76.64 Million | ▼ -6.6 pp |
| 2005 | 83.8% | CN¥255.97 Million | CN¥305.41 Million | CN¥49.44 Million | ▲ +3.6 pp |
| 2004 | 80.2% | CN¥250.42 Million | CN¥312.05 Million | CN¥61.63 Million | ▼ -3.7 pp |
| 2003 | 84.0% | CN¥246.22 Million | CN¥293.21 Million | CN¥46.99 Million | ▲ +16.5 pp |
| 2002 | 67.5% | CN¥85.26 Million | CN¥126.28 Million | CN¥41.02 Million | ▲ +7.4 pp |
| 2001 | 60.1% | CN¥69.48 Million | CN¥115.66 Million | CN¥46.18 Million | ▲ +6.9 pp |
| 2000 | 53.2% | CN¥55.16 Million | CN¥103.67 Million | CN¥48.51 Million | — |